Pipeline

Product
Indication
Discovery
Preclinical
Phase 1
Phase 2
Next Steps
THERAPEUTIC VACCINES
EO2401 + nivolumab
OncoMimics™
Recurrent glioblastoma
Interim data H1 2022
Adrenal
Tumors
Interim data H1 2022
EO2463
OncoMimics™
B-cell Malignancies
Interim data H1 2023
EO4010
OncoMimics™
In progress
Preclinical package
EO2401-1
Phase 2
OncoMimics™

EO2401 is an innovative, off-the-shelf therapeutic cancer vaccine discovered by Enterome.

EO2401 comprises three OncoMimics peptides (bacterial peptides) that are strongly homologous to three key human tumor antigens that are expressed in glioblastoma and adrenal tumors.

EO2401 is being evaluated in two Phase 1/2 clinical trials in combination with a checkpoint inhibitor (nivolumab) for the treatment of glioblastoma (ROSALIE study, EOGBM1-18) and adrenal tumors (SPENCER study, EOADR1-19) with preliminary readouts expected in mid-2022.

MORE INFO
EO2401-2
Phase 2
OncoMimics™

EO2401 is an innovative, off-the-shelf therapeutic cancer vaccine discovered by Enterome.

EO2401 comprises three OncoMimics peptides (bacterial peptides) that are strongly homologous to three key human tumor antigens that are expressed in glioblastoma and adrenal tumors.

EO2401 is being evaluated in two Phase 1/2 clinical trials in combination with a checkpoint inhibitor (nivolumab) for the treatment of glioblastoma (ROSALIE study, EOGBM1-18) and adrenal tumors (SPENCER study, EOADR1-19) with preliminary readouts expected in mid-2022.

MORE INFO
EO2463
Phase 2
OncoMimics™

EO2463 is an innovative, off-the-shelf therapeutic cancer vaccine discovered by Enterome.

EO2463 combines four OncoMimics peptides (bacterial peptides) of B lymphocyte-specific lineage markers. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes enriched in indolent non-Hodgkin lymphoma (iNHL).

EO2463 is being evaluated in a Phase 1/2 clinical trial as monotherapy and in combination with standard-of-care lenalidomide and/or rituximab for the treatment of iNHL (SIDNEY study, EONHL1-20).

MORE INFO
EO4010
Discovery
OncoMimics™

EO4010 is an innovative, off-the-shelf therapeutic cancer vaccine currently in discovery. EO4010 peptides combination will include two OncoMimics (bacterial peptides) already used in EO2401 and one or two additional peptides in an indication with high unmet medical need and market potential.

BIOACTIVES
EB1010
EndoMimics™
IBD, food allergy
Enter clinic in 2023
Sibofimloc
Post-Operative Crohn's Disease
Readout in H1 2023
EB1010
Preclinical
EndoMimics™

EB1010 is an orally administered, GI-selective next generation IL-10 inducer designed to induce high local secretion of IL-10 for the treatment of Inflammatory Bowel Disease (IBD) and food allergy.

EB1010 is a peptide that modulates the immune system by closely mimicking effects of a specific class of hormones.

IL-10 deficiency is central to auto-immune, inflammatory and allergic diseases and a major opportunity exists for an IL-10 inducer that can overcome the limitations of earlier recombinant IL-10 candidates, such as poor stability and tolerability and high systemic dose with limited local exposure.

EB1010 is due to enter the clinic in 2023.

Sibofimloc
Phase 2

Sibofimloc is Enterome’s most advanced pipeline candidate. Enterome believes that sibofimloc has the potential to treat patients with various subsets of Inflammatory Bowel Disease (IBD), including Crohn’s disease, as well as in different therapeutic settings, such as patients with chronic active disease or requiring a maintenance therapy to maintain remission after surgery or other active therapy.

Sibofimloc is advancing through a Phase 2 clinical trial in post operation Crohn’s disease, under a co-development and co-commercialization partnership with Takeda Pharmaceuticals.

 

MORE INFO

OncoMimics™

A potential major breakthrough in therapeutic cancer vaccines

OncoMimicsTM vaccines are a specific combination of bacterial peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid tumors, respectively.



 

Key differentiating factors of OncoMimics therapeutic cancer vaccines include:

  • Expected faster, stronger and durable immune responses
    • Enterome uses non-self bacterial peptides to target tumors which allow us to tap into a pool of memory T cells with pre-existing immune response
  • Excellent immunogenicity
    • Enterome uses the highest possible affinity binding peptides (<10nM) derived from our extensive bacterial protein database
  • Ability to counteract tumor heterogenicity
    • Enterome uses multiple high-affinity peptides in each product targeting multiple key TAAs
  • Expected good safety profile
    • Tumor expression drives OncoMimics selection
  • Potential to access broad patient populations (off-the-shelf)
  • De-risked Chemistry, Manufacturing and Control (CMC) and regulatory paths

EndoMimics™

New generation of oral bioactives to treat inflammatory and autoimmune diseases

EndoMimicsTM are first-in-class orally available bioactives drugs based on proteins secreted by the gut bacteria that act like human hormones or cytokines.

Enterome expects partnering to play a central in generating value from its EndoMimics pipeline.

EndoMimics drug candidates generated are expected to have the following advantages:

  • Novel mode of action based on mimicking the effects or actions of specific hormones or cytokines
  • Potential to treat various immune diseases by accessing a wide range of cellular targets
  • Ability to be fast tracked from screening to preclinical candidate given there is no need for optimization from hit to clinical candidate
  • Excellent safety profile given that microbiome-derived molecules are naturally present in humans leading to the development of low immunogenicity and good tolerance
  • Local delivery and local efficacy as they will be administered in a tailored formulation designed to target release in specific GI region

Partnered Products

Sibofimloc/TAK-018

Sibofimloc is a first-in-class, orally administered small molecule that is specifically designed to reduce the inflammatory cascade underlying Crohn’s disease and remain gut-restricted, to minimize absorption into the bloodstream.

It is designed to reduce inflammation by preventing:

  • FimH-expressing bacteria from adhering to the gut wall,
  • Activation of innate immune receptors,
  • Induction of gut permeability, and
  • Ultimately, inhibiting bacterial translocation through the gut wall

 

Enterome believes that sibofimloc has the potential to treat patients with various subsets of Inflammatory Bowel Disease (IBD), including Crohn’s disease, as well as in different therapeutic settings, such as patients with chronic active disease or requiring a maintenance therapy to maintain remission after surgery or other active therapy.

Sibofimloc is advancing through a Phase 2 clinical trial in post operation Crohn’s disease, under a co-development and co-commercialization partnership with Takeda Pharmaceuticals.

Enterome France

Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Lab facilities
Biocluster Genopole
5 rue Henri Desbruères – 91030 Evry Cedex